CardioDx Leadership Team
Khush F. Mehta | President and CEO
Khush Mehta joined CardioDx in May 2016 as the President & Chief Executive Officer, and a member of the Board of Directors. He brings more than 20 years of strategic, operational, and executive management experience within the healthcare industry. Prior to joining CardioDx, Khush served as the Global Head of the Healthcare Enterprise Solutions at Siemens where he had full-line responsibility for a multi-billion-dollar portfolio of managed services and solutions contracts that included technology, financing, clinical collaborations, project operations, equipment, turnkey services, and risk-based solutions. He has also held additional executive leadership roles at Siemens, including Chief Strategy Officer and Head of Siemens Healthcare, Asia Pacific. Serving as the Chief Strategy Officer of Siemens Healthcare from 2010 to 2014, Khush oversaw strategy implementation, investor relations interactions, venture capital investments, and competitive intelligence. As the Head of Siemens Healthcare, Asia Pacific from 2006 to 2010, he led the P&L and business development for 27 countries in the Asia-Pacific region, spearheading top-line growth while driving significant profit margins for the sector globally. Khush earned a Bachelor and a Master of Commerce and Economics at the Sydenham College in Mumbai, India along with an M.B.A. in competitive strategies and international finance from Yale University.
Timothy Henn | Chief Financial Officer
Timothy Henn joined CardioDx as Chief Financial Officer in September 2015. Mr. Henn brings more than 15 years of executive level experience in the healthcare industry, in both private and public companies, including financing, mergers and acquisitions, as well as broad strategic and operational experience. He most recently served as Chief Financial Officer of Crescendo Biosciences, Inc., which was acquired by Myriad Genetics, Inc. Previously he served in senior finance positions in leading clinical diagnostic and life science companies, including Monogram Biosciences and Incyte Corporation. Mr. Henn holds a B.S. in Accounting from University of Illinois and an M.B.A. from Golden Gate University.
David Levison | Chief Strategy Officer
David founded CardioDx in 2004, and served as the President and Chief Executive Officer of the company until 2016, and is a member of the Board of Directors. Under his leadership of 12 years, he drove the successful commercialization of the Corus CAD blood test, the only blood test to help clinicians determine a patient’s likelihood of obstructive coronary artery disease. Since the introduction of the Corus CAD test in 2009, over 175,000 patients have received and benefited from the Corus CAD test. In 2016, David assumed the role of Chief Strategy Officer of CardioDx where he leads business development, health payer coverage, and development of next generation technologies. Prior to launching CardioDx, David was a Venture Partner at Texas Pacific Group Ventures and was also the interim Chief Executive Officer and Director of CareDx (formerly XDx, Inc.), a molecular diagnostic company focused on the immune system. Previously, he was the Founder, President, and Chief Executive Officer of iScribe, a healthcare technology company acquired by AdvancePCS (now Caremark) in December 2001. Prior to iScribe, David was President of Oncology Therapeutics Network (OTN), which was acquired by Bristol-Myers Squibb in 1996. David also served as Chief Financial Officer of OTN's parent company, Axion, from 1990 to 1993. Prior to Axion, he was with Cole Gilburne Fund, an early-stage, technology-focused venture capital firm. David received his M.B.A. from Stanford University and his B.S. from Williams College. David continues to serve as a Director on both public and private Boards.
Mark Monane, M.D. | Chief Medical Officer
Mark Monane joined CardioDx in 2011 as Chief Medical Officer. Prior to joining CardioDx, he served 11 years as managing director of equity research for Needham & Company, where he focused on analyses of emerging biotechnology companies in the cardiovascular and cancer disease areas. Prior to Needham & Company, Mark served as Senior Director of Medical Policy and Practices at Medco Health. Before joining Medco, he was an assistant professor at Harvard Medical School and the Harvard School of Public Health, where he completed fellowship training in geriatrics, clinical pharmacology, and clinical effectiveness. Mark holds an A.B. and an M.B.A. from Columbia University, an M.S. degree in health policy from Harvard University, and an M.D. from New York University.
Duane Williams | Vice President, Sales and Marketing
Duane Williams joined CardioDx in 2009 as an inaugural member of the Sales team. With his demonstrated leadership and strong sales performance, he progressed into various roles of increasing scope and responsibility, including Regional Manager and Area Director of Sales. As the Area Director of Sales, Duane played a key role in the expansion of the sales organization that involved recruitment of sales representatives, sales training delivery and content management, and marketing strategy. In 2016, Duane was named Vice President of Sales and Marketing of CardioDx. In this role, he leads the commercial strategy, sales and broadening the adoption of the Corus CAD test. Duane has more than 18 years of sales and marketing experience in the healthcare sector. Prior to joining CardioDx, he worked at Pfizer for 11 years, where he was responsible for managing multimillion dollar portfolios across multiple disease areas including Cardiology, Psychiatry, Neurology, Rheumatology, as well as others. Duane holds a B.A. in Communications from Arizona State University.
James Wingrove | Vice President, Technical Operations and Head of Research
James Wingrove joined CardioDx in 2005 and is responsible for overseeing the CardioDx Commercial Laboratory, Biostatistics, Quality, and Process Development groups. In addition, he also leads the company’s research efforts in the development of new diagnostic offerings. Prior to CardioDx, James worked at Incyte Corporation, where he managed a group of scientists in the development and curation of human gene expression and genetic database products. Prior to joining Incyte, James was a Life Science Research Foundation Fellow at the University of California San Francisco, where he explored the genetic pathways underlying oxygen sensing and ischemia. James received his Ph.D. in Biochemistry from the University of California, Los Angeles, and his B.A. in Biology from the University of San Diego. He is a co-inventor of Corus CAD, the company’s first commercial test, and is the author on over 20 scientific publications, including articles in Cell, Science, and Nature.
Susan Daniels, Ph.D. | Vice President, Business Development
Susan Daniels joined CardioDx in 2004, and is responsible for the development of the company's genomic testing products. She has more than 17 years of experience in the genomics industry. Prior to CardioDx, Susan served as Vice President of Curation Sciences at Incyte, where she was responsible for managing the development of genomic-information products. In that role, she managed several multimillion-dollar drug discovery and target validation collaborations with pharmaceutical companies. Prior to joining Incyte, Susan was a Senior Scientist at Axys Pharmaceuticals (formerly Sequana Therapeutics), where she managed projects focused on mapping genes linked to complex inflammatory disorders. Her postdoctoral research was carried out at the Wellcome Trust Centre for Human Genetics at Oxford University. There she completed a genome-wide linkage analysis study that led to the identification of a number of genes associated with asthma. Susan received her Ph.D. in biochemistry from the University of Wales, Cardiff, in the United Kingdom.